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Active Braking of Whole-Arm Reaching Movements Provides
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Movement inhibition is an aspect of executive control that can be studied using the countermanding paradigm, wherein subjects try to
cancel an impending movement following presentation of a stop signal. This paradigm permits estimation of the stop-signal reaction
time or the time needed to respond to the stop signal. Numerous countermanding studies have examined fast, ballisticmovements, such
as saccades, even thoughmanymovements in daily life are not ballistic and can be stopped at any point during their trajectory. A benefit
of studying the control of nonballistic movements is that antagonist muscle recruitment, which serves to actively brake a movement,
presumably arises in response to the stop signal. Here, nine human participants (2 female) performed a center-out whole-arm reaching
taskwith a countermanding component, whilewe recorded the activity of upper-limbmuscles contributing tomovement generation and
braking. The data showa clear response on antagonistmuscles to a stop signal, even formovements that have barely begun. As predicted,
the timingof such antagonist recruitment relative to the stop signal covariedwith conventional estimates of the stop-signal reaction time,
both within and across subjects. The timing of antagonist muscle recruitment also attested to a rapid reprioritization of movement
inhibition, with antagonist latencies decreasing across sequences consisting of repeated stop trials; such reprioritization also scaledwith
error magnitude. We conclude that antagonist muscle recruitment arises as a manifestation of a stopping process, providing a novel,
accessible, and within-trial measure of the stop-signal reaction time.
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Introduction
Sudden events often require the abrupt cancellation of an im-
pending movement. Movement cancellation is an aspect of exec-
utive control that can be studied using the countermanding (or
stop-signal) paradigm (Logan et al., 1994), which requires sub-
jects try to cancel an impending movement following presenta-
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Significance Statement
The countermanding or stop-signal paradigm permits estimation of how quickly subjects cancel an impending movement. Tra-
ditionally, this paradigm has been studied using simple movements, such as saccadic eyemovements or button presses. Here, by
measuring upper limbmuscle activity while human subjects countermand whole-arm reachingmovements, we show that move-
ment cancellationoften involvesprominent recruitmentof antagonistmuscles that serves toactivelybrake themovement, evenon
movements that have barely begun. The timing of antagonist muscle recruitment correlates with traditional estimates of move-
ment cancellation. Because they can be detected on a single-trial basis, muscle-based measures may provide a new way of char-
acterizing movement cancellation at an unprecedented within-trial resolution.
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tion of a stop signal. The countermanding paradigm permits
estimation of the time needed to react to the stop signal (the stop
signal reaction time [SSRT]) (Logan et al., 1984). Although the
SSRT cannot be empirically measured, its estimation provides a
temporal marker to which neural activity can be related, differ-
entiating neural activity plausibly involved in movement cancel-
lation (Hanes et al., 1998; Pare´ and Hanes, 2003; Mirabella et al.,
2011) from that related to involved in performance monitoring or
other aspects of executive control (Scangos and Stuphorn, 2010;
Stuphorn et al., 2010). SSRT estimation also has clinical relevance in
psychiatric disorders characterized by poor inhibitory control, such
asobsessive-compulsivedisorder, schizophrenia, orParkinson’sdis-
ease (Gauggel et al., 2004; Lipszyc and Schachar, 2010).
Movement cancellation has been best studied using rapid, seem-
inglyballistic,movements, suchas saccades (Hanes andSchall, 1995;
Hanes and Carpenter, 1999), button press responses (Logan and
Cowan, 1984; Logan and Irwin, 2000), or utterances (Xue et al.,
2008). Stop signal performance on such tasks is easily categorized
into canceledornoncanceled subtypes.However,manymovements
are not ballistic. For example, whole-arm reaching moves a multi-
segmental body part that is endowed with considerable inertia; the
motion itself also lasts long enough to permit the opportunity for
modification. Reaching movements are under control through-
out their entire trajectory (Georgopoulos et al., 1981), meaning
that an ongoing movement can either be arrested or superseded
by a newmovement inmidflight (for review, see Battaglia-Mayer
et al., 2014; Gaveau et al., 2014). Accordingly, the definition of
cancellation with these and othermanual movements is arbitrary
(de Jong et al., 1990;McGarry and Franks, 2003): is a successfully
canceled movement one that is stopped just before reaching the
movement goal or one that features absolutely no sign of an overt
movement? Complicating matters further, even overtly canceled
movements where no obviousmovement occursmay exhibit ini-
tial patterns of muscle recruitment, meaning that the movement
commands were not fully inhibited (de Jong et al., 1990; Burle et
al., 2002; McGarry and Franks, 2003).
There are potential benefits for studying cancellation of non-
ballistic movements. Chief among these is that cancellation often
requires active braking via recruitment of antagonist muscles
(Kudo and Ohtsuki, 1998; Goonetilleke et al., 2010). If one pre-
sumes that antagonist muscle recruitment arises in response to
the stop signal, then time between the stop signal and the onset of
antagonist recruitment, which we term the antagonist latency,
provides a within-trial measure of the SSRT. In support of this,
during head-free gaze shifts, SSRT estimates for gaze shift cancel-
lation correlate with the timing and variance of the antagonist
latency measured from neck muscles (Goonetilleke et al., 2010,
2012). Such neck muscle antagonist latencies also vary with
immediate trial history (Corneil et al., 2013), showing proactive
adjustments ofmovement cancellation at a single-trial resolution
that surpasses what could be gained via SSRT estimates.
Here, we investigate the relationships between SSRT estimates
ofmovement cancellation and antagonist latencies duringwhole-
arm reaching movements, targeting muscles of the upper limb
that contribute tomovement generation and active braking. Reach-
ingmovements offer a novel platform for studying the correlates of
movement cancellation in the periphery, given the well-known
proximal-to-distal muscle recruitment sequence during whole
arm reaching (Karst and Hasan, 1991). We present a rich dataset
consisting of quantifiable responses to the stop signal in the mo-
tor periphery, even on trials where movements have barely be-
gun. Moreover, an analysis of immediate trial history shows an
unexpected weighting of error magnitude, with larger post-error
adjustments occurring after larger-magnitude errors.
Materials andMethods
Participants. Nine subjects (2 female, mean SD aged 30.2 8.7 years,
all right-handed) participated with informed consent and received pay-
ment. This sample size is somewhat lower than that typically found in
stop-signal studies in humans because of the use of intramuscular fine-
wire electrodes. Participants did not report any neurological deficits, and
all had normal or corrected-to-normal vision. All procedures were ap-
proved by the University Research Ethics Board for Health Science Re-
search at the University ofWestern Ontario and were in accordance with
the Declaration of Helsinki. Participants were aware that they could ter-
minate testing at any time. Two participants (pp3 and pp7, B.D.C. and
J.A., respectively) were authors and hence were knowledgeable about the
specific goals of the experiment. Their results did not differ from the
remaining participants who were naive to the experimental goals. Five
subjects had also never participated previously in either a stop-signal or a
whole-arm reaching study, and their results also did not differ from those
of other subjects.
Apparatus. The reaching apparatus and EMG recording setup have
been described previously (Wood et al., 2015; Gu et al., 2016). Briefly,
participants performed leftward or rightward reachingmovements in the
horizontal plane while holding the handle of a robotic manipulandum
(InMotion Technologies) with the right arm (Fig. 1A). The x and y po-
sitions of themanipulandumwere recorded at 600Hz at a submillimeter
resolution. Stimuli were generated using Tool Command Language. A
custom-built air sled was positioned under the right elbow to reduce
friction. Real-time feedback of hand position was displayed as a red dot
(2.9 mm radius) on a white background by a downward facing LCD
(Sony Bravia KDL-46V3000, output 150 Hz, input 60 Hz), viewed via an
up-facing mirror that obscured view of the hand and manipulandum. A
photodiode, placed at target height at the right edge of the display, re-
corded target and stop-signal onset times. No background loading force
was applied to the arm.
EMG. EMG activity from the clavicular head of the right pectoralis
major (PEC) and posterior deltoid (DELT) were recorded using two
pairs of intramuscular fine-wire electrodes and one surface electrode per
muscle. Both muscles are proximal muscles that span the shoulder joint
and are recruited very early during whole-arm reaching movements
(Karst and Hasan, 1991). In our setup, PEC and DELT are active before
leftward or rightwardmovements of the right arm, respectively (Wood et
al., 2015). In this manuscript, we focus primarily on intramuscular EMG
recordings as its higher signal-to-noise ratio promotes improved detec-
tion of rapid changes in muscle recruitment, although surface EMG re-
cordings led to similar conclusions.We had to rely on surface recordings
of DELT in participants pp1 and pp4, as the intramuscular recordings
were lost during their session. For each intramuscular recording, we
inserted two monopolar electrodes (A-M Systems) staggered by 1 cm
to enable recording of multiple motor units. For PEC, insertions were
aimed 1 cm inferior to the inflection point of the clavicle. For DELT,
insertions were aimed at the middle belly of the posterior deltoid. Intra-
muscular EMG activity was recorded with aMyopac Junior system (Run
Technologies, low-pass filter modified to 2 kHz). Surface EMG was re-
corded with doubled-differential electrodes (DE-2.1, Delsys), placed on
the same muscle fiber belly, but displaced from the intramuscular elec-
trodes. Both the surface and intramuscular EMG signals were digitized at
4 kHz.
Behavioral task. Subjects performed a center-out reaching task with a
countermanding component, which required them tomove to a periph-
eral target on 70% of all trials (no-stop trials), but to try to cancel this
movement when a stop signal appeared (stop trials; 30% of all trials).
Subjects began each trial by reaching to black central stimulus (8.2 mm
radius) that served as the central starting position. After a randomized
delay (1–2 s), a peripheral black target (8.2 mm radius) appeared ran-
domly 0.2 m to the left or right of the central position, at a visual angle of
20° relative to the central starting position (derived from the geometry
of the apparatus). On no-stop trials, subjects were instructed to reach
as soon as possible to the target and had 1.5 s in which to do so. On stop
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trials, the black central stimulus reappeared after a predetermined delay
(stop signal delay [SSD]). Subjects were instructed to try to keep the hand
at the central position on stop trials; hence, they returned their hand to
the central position after small errors. The next trial began after another
randomized delay (1–2 s).
A stop trial was considered successfully canceled when the hand re-
mained within the 0.01 m radius of the starting position, and noncan-
celedwhen the hand crossed the 0.01m radius (Fig. 1B). No feedbackwas
given regarding the outcome of a stop trial. The SSD was varied adap-
tively via a 1-up/1-down staircase with a step size of 28 ms, so that
participants were able to cancel movements within these constraints on
approximately half of all stop trials. This staircasing method will prefer-
entially sample SSDs where p(move)  0.5 and will rarely sample
p(move) 0.2 or p(move) 0.8. SSDs were constrained between 50 and
500ms, and the first SSDwas set to 150ms. Because the input and output
refresh rate of the display did not match, there was some scatter in SSD
timings (SD 15 ms). The actual SSD presented to the subject was used
whenever possible (e.g., for calculation of measures related to antagonist
muscle recruitment).However, because this scatterwould have occasionally
reduced thenumberof observations fromagivenSSDbelow that needed for
the integration method of calculating SSRT, SSDs were binned (16.7 ms
width) for the construction of the inhibition function (see below).
Each participant completed one session with a total of 1600 trials,
preceded by at least 100 practice trials. After each block of 200 trials, the
experiment was paused for at least 2 min. The experiment, including
electrode placement, took2 h.
Analysis of movement kinematics. Data analyses were performed of-
fline. Hand position recordings were analyzed in the left-right dimension
only. Movement RT was defined as the interval between target onset and
the moment the hand departed from a circle of 0.01 m radius, centered
around the starting position. For both the RT measure and the classifi-
cation of stop trials, the same, albeit arbitrary, criterion was used. To
quantify movement amplitude for all trials (including canceled stop tri-
als), we computed the maximum deviation of hand position, relative to
the position at target onset, in the direction of the target within 1 s after
target onset.
Independent race model. Performance in the countermanding para-
digm can be analyzed within the framework of an independent race
model (Logan and Cowan, 1984). In this model, the outcome of a stop
trial depends on which process finishes first: a “go process” initiated
upon target presentation which results in movement generation toward
the target, or a “stop process” initiated by stop signal presentation which
results in movement inhibition. The two processes are assumed to pro-
ceed independently.
One way the SSRT can be inferred is via the “integration method”
(Logan et al., 1994), which requires the RT distribution from no-stop
trials, and the inhibition function that plots the proportion of noncan-
celed trials as a function of SSD (Fig. 1C). At each SSD, the SSRT is
determined by subtracting the SSD from the point that subdivides the RT
distribution into the proportion of noncanceled trials from the inhibi-
tion function. The rationale here, given the assumed independence of the
stop and go processes, is that this point differentiates those trials that
would have escaped inhibition on stop trials (which lie below the point of
subdivision) from those that would have been canceled (above the point
of subdivision) had a stop-signal been provided. As suggested previously
(Logan et al., 1994), we avoided SSDswhere the probability ofmovement
fell below 0.1 or exceeded 0.9. SSRT mean and variance are then derived
from SSRTs estimated at qualifying SSDs. Another way of estimating the
SSRT is to fit a cumulative Weibull function to the inhibition function
(similar to that used in Scangos and Stuphorn, 2010), and the SSD at
which p(move) 0.5 is extracted (we term this the “Weibull method”).
This SSD is then subtracted from the mean of the RT distribution to
extract the SSRT. In theory, SSRTs estimated via bothmethods are equiv-
alent. Consistent with this, SSRT estimates calculated via either method
were very similar within a subject (Table 1). With the exception of some
tests of the independent race model that require SSRT estimates at each
SSD, reported SSRTs are the average of that obtained via the two
methods.
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Figure 1. Experimental setup, countermanding task, and analysis.A, Participants held a roboticmanipulandumwith the right hand. Surface and intramuscular EMG recordingsweremade from
the clavicular head of the pectoralis muscle, and from the posterior deltoid muscle. Stimuli and virtual hand position were viewed via a mirror. B, Each trial started by fixating a central starting
position. After 1–2 s, a target appeared either to the left or right. Subjects moved their hands so that the cursor representing hand position intersected the target stimulus as quickly as possible. In
30% of the trials, the target jumped back to the starting position after an SSD, instructing the participant to try to withhold the plannedmovement. If the hand remainedwithin 0.01m of the start
location, the stop trial was classified as successfully canceled; otherwise, it was classified as noncanceled. C, Depiction of the integration method for estimating SSRT. D, Overview of the kinematic
and EMGmeasures. Movement RT is defined as the time at which the hand crosses the 0.01m radius around the starting location, relative to the time of target presentation. The antagonist latency
is the time from presentation of the stop signal to the onset of antagonist muscle activation.
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Determining the onset and offset of muscle recruitment. Central to our
experimental aim is the timing of changes in muscle recruitment. Defin-
ing both the onset and offset of bursts of EMGactivity within a single trial
at a high temporal resolution is not straightforward, given the variability
of background EMGactivity before target onset, and the fact that recruit-
ment on canceled stop trials can be both brief and small. Rather than
adopting a simple thresholding approach (e.g., based on transitions
across 2–3 SDs above mean baseline activity), we adopted an algorithm
for detecting recruitment timing based on the work by Liu et al. (2015).
This work characterizes the logarithmic distribution of the EMG signal as
a mixture of Gaussian normal distributions, including low-power base-
line distributions and a high-power “burst” distribution (Fig. 2). Using
this Gaussian mixture model, at each time point (0.25 ms steps), a burst
presence probability was estimated for several frequency bands in paral-
lel, and together with a clustering algorithm the burst of interest was
extracted (for full details, see Gaussian mixture model (GMM)). The
algorithm was run from 110 ms after target onset to avoid the stimulus-
locked response (SLR), which is a burst of EMG recruitment time-locked
to peripheral stimulus onset (Pruszynski et al., 2010; Wood et al., 2015;
Gu et al., 2016). All detected onset and offset times were visually inspected
by a trained observer, using a custom-writtenMATLAB program, and cor-
rectedwhere needed (6.7%of instances). Figure 1D provides an overview
of the within-trial measures. The agonist latency is defined as the interval
between target onset and the start of the detected agonist burst. The antago-
nist latency isdefinedas the intervalbetweenstop signalonset and the startof
the detected antagonist burst. We also defined the agonist offset latency as
the interval between stop signal onset and the end of the agonist burst, as an
alternative measure to the antagonist latency. Agonist offset was less pro-
nounced and therefore less reliable than the antagonist onset.
Gaussian mixture model (GMM). The log power signal obtained from
differential EMG electrodes can be modeled by a mixture of Gaussian
normal distributions (Liu et al., 2015). We estimated EMG power by
applying a discrete Fourier transform (4 ms, 16 sample Hamming win-
dow, with 0.25 ms overlap) to produce 9 distinct frequency bands (0,
250–2000Hz). Power values were expressed in decibels referenced to the
band’s mean power as follows:
x  10log10
P
P0
We analyzed EMG activity in the frequency domain because EMG
activity can oscillate in a broad range of frequencies, some of which
contain more information than others regarding the presence of a burst.
Each bandwas initially analyzed separately, with information being com-
bined only at a later step for frequency bands that best informed about
burst presence or absence (see below).
One difference from the method proposed by Liu et al. (2015) is that
we defined three, not two, states of muscle activity: rest (s  1, low
power), baseline activity (s  2, intermediate power), and burst (s  3,
high power). Having three states provided a better characterization of
EMGactivity, particularly during the baseline periodwhere EMGactivity
consisted of brief occasional bursts of activity. Thus, our GMM consists
of three components as follows:
p x  
k1
3
ps  k p x  s  k (1)
where p(s k) is the a priori probability of state k, which is modeled by
parameter 	k (with k13 	k  1), and p(x  s  k) is the conditional
probability distribution of observing log power value x given state k,
modeled by a normal probability density function as follows:
p x  s  k  N x k, k2 
1
k2 e


 x
k2
2k
2
(2)
where k and k
2 are the mean and variance of the Gaussian distribution
for the given hypothesis s k. Using Bayes rule, we can infer the proba-
bility of state k given x as follows:
ps  k  x 
ps  k p x  s  k
p x

	kN x k, k2m13 	mN x m, m2 
(3)
This forms the basis for estimating the burst probability p(s 3  x). The
parameter set 	– 	1,	2,	3, – 1, 2, 3, and – 1, 2, 3 is
estimated for every trial in a series of steps, which follow from the follow-
ing assumptions:
1. In the 500 ms “baseline” period preceding target onset, the state of
the muscle is either rest (s 1) or baseline (s 2), but never burst
(s 3). Thus, the probability density of x in the baseline period can
be estimated with a two-component GMM.
2. If an armmovement ismade toward the target, then the probability
density of x in the 2000 ms period after target onset resembles the
GMM of the baseline period, but with a third component added
(s  3) with 3  2  1. The 2000 ms duration ensures that
muscle activity related to both the outgoing and return movement
is included.
3. We expect the burst state parameters 	3, 3, and 3 to change
slowly over time (e.g., fatigue), whereas the baseline parameters are
expected to change more rapidly from trial to trial (e.g., because of
posture changes).
Fits were performed usingMATLAB’s fminsearch function by maximiz-
ing the log likelihood of the signal under the model (The MathWorks).
The baseline fit provided the trial’s 1, 2, 1, 2 and preliminary weights
	˜1 and 	˜2 (with 	˜2  1 
 	˜1). These weights are termed preliminary
because they were lowered once 	3 was known. Not all trials contain
movements: a muscle may never reach State 3 on a stop trial. Thus, to
estimate the third component (	3, 3, and 3), we used the previous
three no-stop trials, as the muscle must have reached the burst state at
some point on these trials. Using the previous three no-stop trials instead
of a single no-stop trial resulted in more robust fits. For these three
reference trials, the baseline periods were taken together and fitted using
a two-component GMM. Then, for these trials, the 2000ms periods after
target onset were taken together and fitted with the three-component
GMM in which the first two components were adopted from the two-
component fit with their weights (	) fixed proportionally to each other.
Now the full GMM for the reference trials is known, only	3, 3, and 3
are transferred to the current trial’s GMM fit with the first two weights
now being:	1 	˜11
	3 and	2 	˜21
	3.
Once the three-component GMM for a given trial is established, the
probability of the muscle being in burst state at the i’th time point,
psi  3 xi can be computed using Equation 3. However, this ignores
the variability between samples that are close in time. For example, we
assume that muscles will transition into or out of a burst state intermit-
tently. Accordingly, our analysis of burst state probability not only in-
cludes sample xi, but also a few nearby samples tomake the state estimate
more reliable.However, EMGactivitywas Fourier-transformedwith a 16
sample window; hence, samples that are too close in time will already be
highly correlated. Instead, we found that including xi
8, xi, and xi8 into
the computations at time point i provided reliable results. The burst
probability at xi is now given by the following:
Table 1. SSRT values computed for each subject via the integrationmethod or
extracted via theWeibull fit
SSRT (ms)
Subject Integration method Weibull fit Average
1 234 13 235 235.5
2 265 31 283 274.0
3 251 15 249 250.0
4 217 34 213 215.0
5 216 51 215 215.5
6 260 29 266 263.0
7 225 24 223 224.0
8 291 14 299 295.0
9 225 53 225 225.0
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psi  3  x 
psi  3u
11 p xi8u  si  3m13 psi  mu
11 p xi8u  si  m

	3u
11 N xi8u 3, 32m13 	mu
11 N xi8u m, m2  (4)
The parameter and state estimations were performed for all 9 frequency
bands independently. The inferred weighting parameter 	3 provided
information regarding which frequency bands best differentiated the
presence or absence of a burst. If	3  0.005 or	3  0.3, we excluded
the band for that trial because it is unlikely that the muscle was in a burst
state0.5% or30% of the time in the previous go trials.
Next, the overlap of the distribution ps  3 x with the combined
distribution ps  1 x  ps  2 x was estimated for each frequency
band. The frequency bands showing the least overlap were included for the
actual burst detection, as these could dissociate best between the burst and
no-burst states (up to three bands were included). The burst probability
vectors of the included frequency bands were then averaged and trans-
formed into a binary vector: ps  3 x  ps  1 x  ps  2 x.
Because hand kinematics were also recorded, we used the time at
which hand velocity crossed 0.01 m/s in the direction of the target to
constrain the timing of acceptable bursts. The window for acceptable
agonist or antagonist onsets began 150 or 80 ms before this velocity
crossing, respectively. If hand velocity did not cross 0.01m/swithin a trial
(as on canceled stop trials), agonist and antagonist onsets that occurred
up to 1 s after target onset were considered. In addition, the antagonist
onset was only accepted if it occurred after the agonist onset. To remove
noise from the binary vector, sequential bursts (a cluster of adjacent ones)
that totaled4mswere removed. Subsequently, burstswere concatenated if
theywere50ms apart. The first detected burst was considered the burst of
interest, taking into account the constraints noted above.
Data exclusion.A trial was excluded from the analyses when the antag-
onist latency was 350 ms (1.0% of all stop trials) or when the agonist
offset latency was negative (i.e., agonist withdrawal occurred before stop
signal onset) (1.0% of all stop trials) because these occurrences are not
linked to prompt processing of the visual stop signal. Furthermore, when
on visual inspection the burst onset appeared ambiguous because of a
gradual increase in muscle recruitment, or when an initial small move-
ment was followed by a larger movement a few hundred milliseconds
later, the trial was excluded (3.8%). For one participant (pp8), agonist
onsets could not be determined reliably because of tonic cocontraction
before movement onset. Therefore, agonist onset markers of this partic-
ipant were discarded.
Model simulations.We tested aspects of our observed data against that
predicted by an independent race between manifestations of the go and
stop process. To do this, bootstrapping simulations were conducted by
taking random samples from the observed agonist latency (relative to the
go signal), antagonist latency (relative to the stop signal), and the sam-
pled SSD. Each sample of these three values then produced an interval
between agonist and antagonist burst onset, which as an example we
could use to predict the movement amplitude that would be associated
with such an interval (using a fitted cumulative Gaussian).
Experimental design and statistical analysis. All statistical analyses were
performed in MATLAB (version R2104b, The MathWorks). When ap-
plicable, results are expressed as mean  SD, unless otherwise noted.
Comparisons of within-subject or across-subject results were conducted
via paired or two-sample t tests, respectively. Pearson’s correlation was
used to correlate various measures, as reported in Results. The level of
significance was set to p 0.05. Effect sizes are reported as Cohen’s d for
t tests and partial 	 2 for ANOVAs.
Results
We studied muscle recruitment during whole-limb reaching
movements in a countermanding task. We hypothesized that the
timing of antagonist muscle recruitment arises from the comple-
tion of the stop process and, hence, should relate to both stop
Figure 2. Burst detection algorithm. A discrete Fourier transformwas applied to get EMG power in several frequency bands (one band is shown here). The power distributionwas parameterized
using three normal distributions: two baseline distributions (blue), which are fitted on the baseline period (500 ms before target onset); and one burst distribution with higher power (red), which
complements the baseline fit to describe the trial period (which runs for 2 s after target onset). At each trial, these distributions were fitted anew using the previous three no-stop trials (one trial
shown). From this fit, only the burst distribution was used, together with the baseline fit of the current trial, to compute the burst probability over time. The burst probability vectors of the three
frequency bands that dissociated best between burst and baseline were averaged to get to a single p(burst) vector. Finally, using a low pass filter, the burst of interest was extracted. For further
details, see Materials and Methods.
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signal onset and the estimated SSRT. First, we describe behavior
on thebasis of handposition recordings in the conventionalmanner
used in countermanding studies. Then we present the patterns of
muscle recruitment on agonist and antagonist muscles. We con-
clude with an investigation of the agonist and antagonist recruit-
ment latencies with trial history, to examine whether they
provide evidence for proactive and opposing adjustments in pro-
cesses related to movement generation and inhibition, as has
been reported previously in neck muscles during control of ori-
enting eye-head gaze shifts (Corneil et al., 2013).
Continuous control of reaching
Figure 3 shows the horizontal component of hand movement
traces of a representative participant. In this plot, each trace rep-
resents a single trial, aligned to the onset of either the right or left
target. In the no-stop trials (Fig. 3A), movement amplitudes scat-
ter around the target (rotated histograms to the right of the
movement traces). As expected, there is substantial variance in
movement RT, as summarized by the respective RT distributions
above or below the movement traces.
In stop trials, the target suddenly jumps back to the central
position after a variable SSD, instructing the participant to try to
withhold the movement. The data in Figure 3B, C are further
segregated based on whether the participant generated a move-
ment beyond the 0.01m criterion (Fig. 3B, noncanceled trials) or
not (Fig. 3C, canceled trials). For this participant, the SSD ranged
between 125 and 425ms (color-coded SSD histograms just above
position traces; note preferential sampling of intermediate SSDs).
A substantial proportion of noncanceled movements failed to
attain the target but were arrested in midflight (e.g., compare
movement amplitude histograms in Fig. 3A,B). Furthermore,
noncanceled trials have shorter RTs than no-stop trials (compare
RT histograms in Fig. 3A,B; no-STOP RTs  501  77 ms,
noncanceled RTs 463 75 ms; two-tailed t test t(1250) 6.56,
p  10
10, Cohen’s d  0.51), suggesting that presumably long
RT movements can be canceled on trials with long SSDs. The
color coding of the movement RT distributions supports this
supposition: for short SSDs (red/orange), only movements with
short RTs escape inhibition. In contrast, the movement traces on
canceled trials barely deviate at all (Fig. 3C), and there are more
canceled trials with early SSDs compared with noncanceled
trials, and more noncanceled trials with late SSDs than can-
celed trials. Thus, as expected, the probability of successfully
canceling a movement increases the earlier the stop signal is
presented.
As mentioned, the reach behavior of this participant was rep-
resentative of our sample. To show this, Figure 4 illustrates the
movement amplitudes of all participants on no-stop trials (Fig.
4A) versus noncanceled stop trials (Fig. 4B). Note how move-
ment amplitude for noncanceled trials ranged from the target
location down to the 0.01 m boundary between canceled and
noncanceled movements. This observation reinforces the non-
ballistic nature of these whole-arm reaching movements, so that
ongoingmovements can be canceled at any point before reaching
the target.
In Figure 5, we quantify a number of other observations both
for the representative participant (top row) and across our sam-
ple (bottom row). The inhibition functions (Fig. 5A,B) show the
proportion of noncanceled stop trials as a function of SSD; and as
expected, the proportion of noncanceled trials increaseswith lon-
ger SSDs (Lappin and Eriksen, 1966). All participants exhibited
this pattern, although there was substantial intersubject variabil-
ity in where this function was centered along the x-axis (Fig. 5B),
in part due to how quickly subjects reacted on no-stop trials. These
inhibition functions are primarily centered near p(move) 0.5 and
didnot extend to p(move) 0.1 or p(move) 0.9; this is due to our
use of the one-up/one-down stepping procedure used to determine
the SSD on the next trial. The inhibition function can be used
along with the RT distributions to estimate the SSRT, or the time
needed to react to the stop signal. Across our sample, SSRTs
derived from the integration method and Weibull method were
very similar (Table 1; linear regression, r 0.970, t(7) 16.235,
p  10
6), justifying averaging. SSRTs averaged 244  28 ms
(mean SD), ranging from 215 to 295 ms, which conforms well
with previously reported SSRTs for a variety of manual responses
(Mirabella et al., 2006; Boucher et al., 2007; Brunamonti et al.,
2012).
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Movements conform to the independent race model
The independent race model makes a number of predictions about
reaching behavior that we can test against our observations. For
example, the independent race model predicts that SSRTs should
decrease for longer SSDs because only those stop processes that
proceed faster can produce movement inhibition in such cases
(Logan and Cowan, 1984). To test this, we used the integration
method to estimate the SSRT at each SSD and plotted this as a
function of SSD. As shown for our representative participant
(Fig. 5C) and across our sample (Fig. 5D), SSRTs did decrease as
a function of SSD (a significantly negative correlation was ob-
served in 7 of 9 subjects, at p 0.05).
According to the independent racemodel, the RT on noncan-
celed trials at a particular SSD should be predicted by subdividing
the no-stop RTs into the proportion of trials that would or would
not have escaped inhibition, had a stop signal been provided at
that particular SSD (Fig. 1C) (Logan and Cowan, 1984); a corol-
lary of this test is that RTs on noncanceled trials should increase
for longer SSDs because longer SSDs permit more slowly pro-
ceeding go processes to still escape inhibition. Across our sample,
the observed RTs of noncanceled trials did increase with SSD
(Fig. 5E,F, linear regression, r  0.855, slope  0.614, t(86) 
15.29, p 10
25; a significantly positive correlationwas observed
in 7 of 9 subjects, at p 0.05), although we found that the trend
in observed RTs was generally steeper than predicted, with RTs at
higher SSDs being particularly underestimated (Fig. 5E).
Finally, our observation of highly variable amplitudes for
noncanceled movements is consistent with both the nonballistic
nature to these movements and the continued processing of the
stop signal after the movement is launched. We found a straight-
forward relationship between movement amplitude and SSD:
movement amplitudes tended to be greater for longer SSDs, both
in our representative participant (Fig. 5G) and across our sample
(Fig. 5H) (all positive correlations, p  0.05). The relationship
between movement amplitude and SSD was accurately captured
with our simulation of the independent race model for 8 of our 9
subjects (Fig. 5H, lines indicate simulation results). All correla-
tions between observed and simulated data were significant at
p 0.005; r values exceeded 0.9 for 8 subjects but was 0.75 for the
subject shown by the brown line.
Muscle recruitment on no-stop trials
Having established that participants performed in amanner con-
sistent with an independent race model, we now turn to the pro-
file of muscle recruitment accompanying this task. In particular,
we address whether changes in muscle recruitment provide a
proxy of movement cancellation.
We measured surface and intramuscular EMG activity of the
right PEC and DELT muscles, which in our setup contribute to
either leftward or rightward planarmovements of the right upper
limb as an agonist muscle, respectively, and would be expected to
actively brakemovements proceeding in the opposite direction as
an antagonist muscle. Figures 6 and 7, respectively, show intra-
muscular PEC and surface DELT activity recorded from the same
subject during the classified trials types (no-stop, noncancelled,
and canceled), vertically stacked by either movement RT (Figs.
6A–D, 7A–D) or movement amplitude (Figs. 6E,F, 7E,F). These
figures are organized in a muscle, rather than direction-specific
fashion; hence, the appreciation of how the muscles work together
can be gained by comparing Figure 6 (left column) with Figure 7
(right column), or vice versa. SurfaceEMGrecordings are shown for
DELT in this example because intramuscular recordingswere lost
with this participant; we also wish to emphasize that similar ob-
servations can be made using either intramuscular or surface
recordings.
We focus first on the recruitment of these muscles during no-
stop trials, aligned to target onset and vertically sorted bymovement
RT. As expected of agonistmuscles, large bursts of activity preceded
movement onset, leading leftward movements by 123 ms for PEC
(Fig. 6A) and leading rightward movements by 112 ms for DELT
(Fig. 7A). Across our sample, the lead between agonist onset and
RT tended was greater for PEC than DELT (157 32 and 137
26 ms, respectively, paired t test, t(8) 4.37, p 0.002). For each
subject, the burst onset in both muscles was highly correlated
with the direction-appropriate RT on a trial-by-trial basis (linear
regressions, r2 0.86 0.17, PEC; and r2 0.92 0.076,DELT;
all p  10
58). Similarly, when these muscles served as antago-
nists on no-stop trials, they both exhibited a prominent burst of
activity that led movement offset across our sample by 254 38
ms (PEC; Fig. 6B) or 262 33ms (DELT; Fig. 7B). These profiles
of recruitment resemble the first two phases of the triphasic pro-
file of activation that accompany rapid goal-directedmovements
of an inertial object (Hallett et al., 1975); the third phase of ago-
nist muscle recruitment is visible for the shortest latency move-
ments in Figures 6A and 7A.
One other aspect of PEC muscle recruitment that is apparent
on no-stop trials is the banding that begins100 ms after target
presentation, with activity increasing (Fig. 6A) or decreasing (Fig.
6B) after leftward or rightward target presentation, respectively,
before progressing through a series of 15 Hz oscillations in
advance of the main burst of muscle recruitment. This feature is
the SLR (Pruszynski et al., 2010; Wood et al., 2015; Gu et al.,
2016). An SLR was observed in 8 of 9 participants on PEC and in
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2 of 9 participants on DELT. Our analyses of agonist and antag-
onist burst onsets began after the SLR (110 ms after target
onset).
Muscle recruitment on stop trials
We now examine the profiles of muscle recruitment observed on
stop trials (Figs. 6C–F, 7C–F), subdividing such data based on
target direction and into noncanceled or canceled stop trials
(above and below the dashed line, respectively). Stop trial data in
Figures 6 and 7 are aligned either to target (Figs. 6C,D, 7C,D, cyan
lines or dots) or stop signal onset (Figs. 6E,F, 7E,F, red lines or
dots). On noncanceled trials, we observed a straightforward rela-
tionship between stop signal onset and agonist muscle recruit-
ment: late noncanceled movements escaped inhibition only
when the stop signal was late (Figs. 6C, 7C). On such trials, ago-
nist muscle activity commenced as expected but exhibited a
shorter burst duration compared with no-stop trials (123  30
ms compared with 207 83 ms, mean SD across participants,
paired t test, t(8)  3.61, p  0.007); on such trials, antagonist
muscle activity relative to the agonist onset also started earlier
comparedwith no-stop trials (149 26ms comparedwith 242
75 ms). These features (foreshortening of the agonist burst, ear-
lier antagonist recruitment) are consistent with the arm move-
ments being arrested in mid-flight.
Two further observations of muscle recruitment on stop trials
are important to note. First, as is particularly apparent in Figure
6C, D, the SLR preceded stop signal appearance and, hence, per-
sisted regardless of whether a stop signal was present or not.
Second, there were a number of instances of detectable muscle
recruitment even on canceled trials, in which the hand did not
leave the starting position (traces below dashed lines: Figs. 6C–E,
7C–E). This was a consistent observation across all subjects in our
sample, as shown in Table 2. A cessation of the agonist recruit-
ment was detected on 39  15% (PEC, mean  SD across par-
ticipants) and 35  19% (DELT) of canceled trials, whereas
antagonist activation was detected on 67 10% (PEC) and 41
24% (DELT) of canceled trials; the magnitudes of such recruit-
ment can be quite subtle on canceled trials, when aligned to target
onset (Figs. 6C,D, 7C,D). Clearly, despite the absence of overt
movement of the limb, both PEC and DELT are being recruited
on just over half of all canceled stop trials. Thus, movement can-
cellation does not imply the absences of changes in muscle re-
cruitment; however, changes in muscle recruitment did not
always accompany movement cancellation.
Next, we asked whether the timing of muscle events, and in
particular the timing of antagonist onset, relate to the timing of
the stop signal. To examine this, we realigned stop-trial data on
stop signal onset (Figs. 6E,F, 7E,F). This tightened the trial-by-
trial variability in the timing of antagonist muscle onset (e.g.,
Figs. 6F, 7F, magenta histograms) and agonist muscle offset (e.g.,
Figs. 6E, 7E, orange histograms), compared with the variability
observed when these features are aligned to target onset (Figs.
6C,D, 7C,D). Realigning the data in this way also makes the level
of antagonist muscle recruitment on canceled trials more appar-
ent (Fig. 6F). Across our sample, realigning data to stop signal
onset reduced the SDs of the antagonist onset distributions by a
factor of 1.78 0.91 for PEC (paired t test, t(8) 4.47, p 0.002)
and 1.85  1.05 for DELT (t(8)  4.74, p  0.002). The agonist
offset distributions were reduced in a similar way (PEC: 1.79 
1.01, t(8) 4.87, p 0.002; DELT: 1.60 0.61, t(8) 4.01, p
0.004). Across participants, the average antagonist latencies rela-
tive to stop signal onset were 182 16 ms for PEC and 195 18
ms for DELT. Average agonist offset latencies were 165 22 ms
for PEC and 164 18 ms for DELT. Although the agonist offset
relative to the stop signal may theoretically provide anothermea-
sure of movement cancellation, in practice this measure was less
reliable than that provided by antagonist onsets in our experi-
mental configuration. Evidence for this point can be found by
comparing the proportion of trials from which a given muscle
can yield a quantifiable change in muscle recruitment when
acting as an agonist or antagonist (Table 2); across our sample,
measures of antagonist muscle recruitment were available on a
larger proportion of trials (paired t test, t(17) 4.69, p 0.0002).
When both agonist offset and antagonist onset were present on
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the same trial for canceled and small noncanceled trials (0.05 m),
the duration between these measures was 25 18 ms, with 93%
of these observations being0. Thus, the agonist and antagonist
muscles were rarely coactivated, perhaps due to spinal circuits
that prevent cocontraction in this task.
The trials in Figures 6E,F, and 7E,Fhave been stacked in order
of increasing movement amplitude; this is possible even for can-
celed trials, which featured movements that did not exceed the
position threshold. Ordering trials this way reemphasizes how
larger movements are associated with earlier agonist onsets (blue
dots) relative to the stop signal (i.e., note how agonist muscle
bursts start earlier for larger noncanceled trials). In contrast, both
agonist offsets and antagonist onsets related tomovement ampli-
tude in a reciprocal way: the earlier the antagonist onset, the less
motion occurred (Figs. 6F, 7F). Further, note as well that the
antagonist onsets relative to the stop signal do overlap for non-
canceled and canceled trials (Fig. 6F); we attribute this overlap to
the variability in reacting to both the target and to the stop signal,
the SSD, to the ambiguity in differentiating noncanceled from
canceled trials, and to the continued processing of the STOP
signal after movement onset.
Although not visible in Figures 6 and 7 because of the chosen
grayscale, we also observed that antagonist muscle recruitment
on stop trials was brisker than onno-stop trials, ramping upmore
quickly to the peak level of within-trial recruitment. This is illus-
trated in Figure 8, which shows the average burst profile of the
agonist (Fig. 8A) and antagonist (Fig. 8B) muscles, pooled across
participants, for no-stop trials and for stop trials associatedwith a
variety of differentmovement amplitudes. The initial100ms of
agonist muscle recruitment (Fig. 8A) was largely similar on no-
stop trials and larger noncanceled movements (Fig. 8A, red and
green traces) but muted for smaller noncanceled movements
(Fig. 8A, blue traces). In contrast, the initial100 ms of antago-
nist muscle recruitment was gradual on no-stop trials, peaking
80 ms after burst onset, but sharp on noncanceled movements
regardless of movement amplitude, peaking within30 ms (Fig.
8B). The peak of antagonist muscle recruitment was also largest
on the noncanceledmovements of intermediate amplitudes (Fig.
8B, green lines). Our interpretation of this result is that antago-
nist muscle recruitment actively brakes the ongoing limb move-
ment on trials altered in mid-flight in an acceleration- and/or
velocity-dependent manner, requiring more recruitment on in-
termediate (Fig. 8B, green traces) versus small (Fig. 8B, blue
traces) noncanceled. However, because some of the larger (Fig.
8B, red traces) are nearing completion, they may already be de-
celerating at the time a braking pulse is required, which is why
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there is a smaller recruitment peak on larger-amplitude noncan-
celed trials. To further support our contention that antagonist
muscle recruitment actively brakes the ongoing limb movement
on many stop trials and is not simply linked to the triphasic
pattern of recruitment seen on no-stop trials, we calculated the
slope from burst onset to peak EMG activity. When examining
the agonist muscle activity, we found no difference in the slope
for no-stop trials compared with the average slope of the stop
trials across different movement amplitudes (paired t test, t(8)
0.51, p 0.62). However, we did find a steeper slope for antago-
nist muscle recruitment on stop trials compared with no-stop
trials (t(8) 3.83, p 0.005).
Together, these finding support our hypothesis that charac-
teristics of muscle recruitment, such as the antagonist onset, pro-
vide a proxy measurement of the stop signal RT.
Antagonist latencies relate to SSRTs
Wenow turn to relationships between the antagonist latency and
the SSRT, testing the hypothesis that the antagonist onset pro-
vides a proxymeasurement for stopping. If so, one would predict
similar variations in SSRT and antagonist latency across and within
subjects. As predicted, mean antagonist latencies correlated with
SSRTestimates on a subject-by-subject basis (Fig. 9A; linear regres-
sion, r  0.852, slope  0.828, t(7)  4.31, p  0.005): subjects
with longer SSRTs tended to have longer antagonist latencies. On
average, antagonist latency preceded the estimated SSRT by 45
5 ms (mean  SEM). Although it may seem curious that SSRT
exceeds the antagonist latency, changes in muscle recruitment
can precede SSRTs in manual response tasks (Scangos and Stu-
phorn, 2010); and as mentioned in Discussion, SSRTs vary de-
pending on the criterion separating canceled from noncanceled
movements on stop trials.
We also wished to examine how the antagonist latency related
to the SSD because, as predicted by the independent race model
(and as seen for the relationship between SSRT and SSD shown in
Fig. 5D), longer SSDs permit less time for stopping. However,
conducting this analysis is potentially confounded by movement
amplitude because, as noted above, smaller amplitude move-
ments tend to be associated both with shorter SSDs (Fig. 5G,H)
and with shorter antagonist latencies (e.g., Fig. 6F, position of
pink dots relative to red line, stacked as a function of movement
amplitude). To circumvent this potential confound, we exam-
ined the relationship between antagonist latency and SSD for
movements binned into 0.025 m amplitude bins and then aver-
aged the antagonist latencies across all participants. As shown in
Figure 9B (with SSDs grouped into quartiles for convenience),
antagonist latency tended to decrease with increasing SSDs over
most movement amplitudes, although we did not test the signifi-
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cance of this correlation because there were only four data points.
Thus, providing one accounts for howmuch the handmoves before
being stopped, the antagonist latency appeared to decrease for later
SSDs.
To directly compare antagonist latency and SSRT, we split the
SSDs into quartiles and then plotted the observed antagonist
latency against the estimated SSRT at each quartile. As shown in
Figure 9C, doing so revealed a positive relationship between an-
tagonist latency and SSRT in 7 of 9 participants, although we did
not test the significance of this correlation because there were
only 4 data points.
Finally, we wished to examine whether there were relation-
ships between the SSRT and antagonist latency. We found that
the antagonist latency and SSRT tended to cofluctuate through
time, as participants shifted priority between going and stopping
over the course of the experiment (Bissett and Logan, 2011; Cor-
neil et al., 2013). To analyze this aspect of our data, we compared
the estimated SSRT and the mean antagonist latency in each of
the eight blocks of 200 trials. In all participants, we observed a
positive relationship between antagonist latency and SSRT (Fig.
9D; this correlation reached significance in 1 of 9 subjects, at p
0.05), meaning that blocks with longer SSRTs tended to have
longer antagonist latencies.
Opposing and scaled post-error adjustments across different
movement sequences
We now turn to analyses that would not be possible using conven-
tional estimates of SSRT, given that such estimates require many
trials. A well-documented effect in countermanding tasks is post-
error slowing of the RT on no-stop trials (Emeric et al., 2007;
Enticott et al., 2009; Bissett and Logan, 2012b). Previous work on
countermanding eye-head gaze shifts has shown that the antago-
nist latency on neck muscles is also adjusted based on recent trial
history, but in a direction opposite to that observed for RTs (Cor-
neil et al., 2013). Such results were attributed to strategic and
opposing shifts in the balance betweenmovement generation and
inhibition. Here we looked for a similar trial history effect on
both movement generation and inhibition using a “triplet anal-
ysis” (Nelson et al., 2010) that allows assessment of the change in
agonist latency relative to target onset, or antagonist latency rel-
ative to stop signal onset, across different trial sequences (Fig.
10A). The triplet analysis permits pooling of results across partic-
ipants because all measures are referenced to the n
 1 trial.
The effect of trial history on movement generation was as-
sessed via the change in the agonist latency (Fig. 10B, blue bars).
In agreement with previous studies (Nelson et al., 2010; Corneil
et al., 2013), agonist latency decreases across a no-stop–no-stop–
no-stop sequence (Fig. 10B, left; one-sample t test, t(4074) 

14.7, p 10
46), reflecting a hastening in movement genera-
tion across no-stop trials with an intervening no-stop trial. In
contrast, if the intervening trial was a stop trial, agonist latency
increased (one-sample t test, t(1813) 6.04, p 10

8).Moreover,
this post-error slowing across such sequences scaled with move-
ment amplitude (Fig. 10B, right), being moderate for small
movements (which would include canceled and small-amplitude
noncanceled trials) and progressively larger for larger-amplitude
noncanceled movements (linear regression; r  0.14, t(1812) 
6.05, p  10
8). Thus, not only was the movement generation
process delayed after an intervening stop trial, but themagnitude
of the delay scaled with the magnitude of any error that the sub-
ject made on the intervening trial.
We conducted a similar analysis on antagonist latency. We
found that the antagonist latency tended to decrease across an
intervening stop trial, with a larger decrease occurring when the
subject produced a larger error on the intervening stop trial (Fig.
10B, right; linear regression; r  
0.26, t(127)  
3.21, p 
0.002). Thus, in contrast to what was seen with the movement
generation process, the movement inhibition process was expe-
dited after an intervening stop trial, with the magnitude of such
an adjustment scaling with error magnitude on the intervening
Table 2. Number of movement sequences on stop-trials, and the number and proportion of trials fromwith either agonist offset or antagonist muscle onset could be
extracted on canceled stop trialsa
PEC as agonist (leftward movement) PEC as antagonist (rightward movements)
Subj.
No. of stop
trials
No. of
noncanceled
No. of
canceled
No. of agonist
offset
% agonist
offset
No. of stop
trials
No. of
noncanceled
No. of
canceled
No. of
antagonist offset
% antagonist
offset
1 234 110 124 45 36.2 235 115 120 72 60.0
2 217 94 123 49 39.8 223 110 113 74 65.4
3 229 185 44 17 38.6 236 130 106 84 79.2
4 219 91 128 41 32.0 225 110 115 68 59.1
5 224 86 138 50 36.2 236 127 109 74 67.8
6 231 100 131 43 32.8 235 126 109 66 60.5
7 229 79 150 48 32.0 232 142 90 47 52.2
8 231 122 109 85 77.9 236 107 129 107 82.9
9 232 97 135 37 27.4 240 127 113 82 72.5
39 15 67 10
DELT as agonist (rightward movements) DELT as antagonist (leftward movements)
1 235b 115b 120b 23b 19.1b 234b 110b 124b 42b 33.8b
2 223 110 113 35 30.9 217 94 123 46 37.3
3 236 130 106 61 57.5 229 185 44 29 65.9
4 225b 110b 115b 21b 18.2b 219b 91b 128b 21b 16.4b
5 236 127 109 38 34.8 224 86 138 66 47.8
6 235 126 109 21 19.2 231 100 131 17 12.9
7 232 142 90 34 37.7 229 79 150 67 44.6
8 236 107 129 95 73.6 231 122 109 95 87.1
9 240 127 113 29 25.6 232 97 135 28 20.7
35 19 41 24
aData are presented in a muscle-specific fashion, following the convention in Figures 6 and 7. PEC acts as an agonist on leftward movements and an antagonist on rightward movements (vice versa for DELT). Summary data presented as
mean SD.
bData extracted from surface recordings.
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trial. Finally, in contrast to previous findings (Corneil et al., 2013),
the antagonist latency decreased if an intervening trial was a no-
stop trial (Fig. 10B, left; one-sample t test, t(414)  
2.30, p 
0.022). Our failure to replicate previous findingsmay relate to the
effect of movement amplitude on the n
 1 and n 1 stop trials
on the antagonist latency, which could obscure any effects on trial
history.
In sum, we found evidence for opposing trial-to-trial adjust-
ments in both the agonist and antagonist latency across trial se-
quences with an intervening stop trial, in line with opposing
reprioritization of movement generation or inhibition with
immediate trial history. The opposing directions of these scaled
adjustments on measures of movement generation and inhibi-
tion across an intervening stop trial can be best appreciated in
Figure 10B (right), as the adjustments of agonist or antagonist
latency increase or decrease, respectively.
Fewer trials are required to assess the latency of stopping
using antagonist latency versus the SSRT
In the final analysis, we examine how many trials are required to
obtain accurate measures of either the antagonist latency or SSRT.
To address this, we performed post hoc simulations in which “x”
number of trials was randomly taken from the dataset. Under the
assumption that after 1600 trials (with 30% stop trials), we ob-
tained the true value of the SSRT or antagonist latency, we asked
how many trials would be required to obtain measures than lay
within an arbitrary 10 ms of this true value. Across our sample,
440 98 total trials (mean SEM, with 30% stop trials, or132
stop trials across all SSDs) were required to derive SSRTs within
10 ms of the true value. This finding compares favorably to the
simulation results reported by Band et al. (2003), where it was
shown that 50 stop trials per SSD are required to yield SSRT
estimates with 95%CIs of10ms. In contrast, only 64 14 total
trials (or19 stop trials) were required to obtain average antag-
onist latencies within 10 ms of the true value. This analysis illus-
trates that the antagonist latency could be used to provide amore
rapid assessment of inhibitory control than that currently used
via estimation of the SSRT.
Comparing results from surface versus intramuscular
recordings
Our analysis largely, although not exclusively, relied on EMG re-
cordingsmade via intramuscular electrodes. The output of the burst
detection algorithmwas also screened on a trial-by-trial basis. Given
that intramuscular recordings are invasive (which limited our sam-
ple size) and trial-by-trial screening time-consuming, we investi-
gated whether similar conclusions could have been reached from
surface recordings, andwithoutmanual screening. To do this, we
took advantage of the fact that PEC was recorded via two sets of
intramuscular recordings (the “selected” and the “unselected”
channel; for the selected channel, we reverted to measures ob-
tained directly from the burst detection algorithm, beforemanual
screening) and one surface recording. We then compared the
mean antagonist latency obtained from each of these three chan-
nels to each other and to the SSRT. As expected, all muscle mea-
sures correlatedwell with each other on a subject-by-subject basis
(Table 3); hence, subjects with longer antagonist latencies with
the selected intramuscular recording tended to have longer an-
tagonist latencies with unselected surface recording (linear re-
gressions, r 0.76, p 0.01 for the three possible comparisons).
Antagonist latencies measured via surface recordings tended to
be longer than those obtained from the selected (paired t test,
t(8)  4.71, p  0.0015) but not unselected (paired t test, t(8) 
2.11, p 0.07) intramuscular recordings, and the values from the
selected and unselected intramuscular recordings did not differ
significantly (paired t test, t(8)  1.30, p  0.22). Finally, the
positive correlation between SSRT and the antagonist latency
remained regardless of whether the antagonist latency was de-
rived from the selected intramuscular recording (Fig. 11A; linear
regression, r  0.75, slope  0.31, t(7)  3.01, p  0.02), unse-
lected intramuscular recording (Fig. 11B; linear regression, r 
0.78, slope 0.43, t(7) 3.30, p 0.01), or the surface recording
(Fig. 11C; linear regression, r  0.67, slope  0.36, t(7)  2.38,
p 0.05; compare both with Fig. 9A).
Using agonist muscle offset to assess movement cancellation
As mentioned above, movement cancellation was often associ-
ated with a cessation of agonistmuscle recruitment that preceded
antagonist muscle onset, on average by 25 ms. The analyses
shown in Figures 9 and 10 relied on the timing of antagonist
muscle recruitment relative to the stop signal, given that this
measure was obtained on a higher proportion of stop trials. We
repeated the same analyses using the timing of agonist muscle
offset, and observedmany of the same tendencies, although these
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Figure 8. Averaged rectified EMG activity aligned to burst onset for no-stop (black traces)
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tendencies approached but did not reach significance. Briefly, the
mean of the agonist offset latency correlated on a subject-by-
subject basis with the SSRT (subject-by-subject correlation of
means: r  0.76, slope  0.78, t(7)  2.15, p  0.018; compare
with Fig. 9A). However, presumably due to the fewer observa-
tions from which an agonist offset latency could be derived,
block-by-block correlations between ago-
nist offset and SSRT trended upward in
only 6 of 9 subjects (as opposed to 9 of 9
subjects when using the antagonist onset;
Fig. 9D), and the agonist offset latency did
not trend downward across a stop trial in a
manner that depended on the movement
amplitude in the intervening trial, as was
the case for the antagonist onset in Figure
10B. Thus, although aspects of movement
cancellation appear accessible with ago-
nist muscle offset, antagonist muscle on-
set provided a more reliable measure in
our experimental configuration that per-
mitted a finer-grained assessment of move-
ment cancellation.
Discussion
We studied the cancellation of whole-arm
reaching movements in humans while re-
cording upper limb activity from agonist
and antagonist muscles. The timing of
changes in muscle recruitment relative to a
stop signal provides a within-trial measure
of the stopping latency. Such measures can
be obtained via surface recording tech-
niques, converge on stable values within
100 total trials, and enable examinationof
the prioritization of stopping at an unprec-
edented resolution.
Mid-flight cancellation of an inertial
body segment
The limb has considerable inertia, which
imposes a lagbetween thechanges inmuscle
recruitment and changes in movement ki-
nematics. Moreover, the whole-arm reach-
ing movements studied here lasted 300
ms. Accordingly, such whole-arm reaching
movements can be stopped at any point in
mid-flight, ranging from instances where
the movement has barely begun to those
where the stop signalwaspresented after ag-
onist muscle onset (Fig. 4B). Clearly, the
stop signal continues to be processed after
movement commitment. Movement dura-
tion may be a crucial factor determining
whether a movement is ballistic or not;
whereas small-amplitude saccades offer
limited time for control, larger eye-head
gaze shifts can be arrested or adjusted in
mid-flight (Corneil et al., 1999; Corneil and
Elsley, 2005).
The wide range of amplitudes on stop
trials emphasizes the arbitrariness of the
criterion dividing stop trials into canceled
or noncanceled subtypes. Our 1 cm crite-
rion (5% of movement amplitude on
no-stop trials) produced SSRT estimates similar to those re-
ported previously (Mirabella et al., 2006; Boucher et al., 2007;
Brunamonti et al., 2012). Post hoc analysis showed that SSRTs
would have increased by 42 17ms (mean SD) or 72 34ms
had we used a stopping criterion of either 50% of 95% of the
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entire movement amplitude, respectively. Shorter SSRTs that
match or precede the antagonist latency could be obtained by
constraining the stopping criterion even further. The arbitrari-
ness of what constitutes success in a nonballistic system, and the
associated changes in SSRT estimates, are relevant for neurophys-
iological studies of stopping, where the SSRT differentiates whether
candidate neural activity could be involved inmovement control or
not. The confidence one has in applying this logic depends on how
closely the SSRT matches central processes related to movement
inhibition. Measuring changes in muscle recruitment offers an
alternative, empiricalmeasure ofmovement inhibition that is less
prone to arbitrariness: any central stopping process must neces-
sarily precede changes in peripheral muscle recruitment for it to
contribute to movement control.
Although our SSRT estimates compare favorably with previ-
ous reports, the types of manual responses are quite different.
Manual responses studied in the countermanding framework in-
clude squeezes of a dynamometer (de Jong et al., 1990), keyboard
presses (Logan and Irwin, 2000), deflections or movements of a
joystick or manipulandum (Boucher et al., 2007; Scangos and
Stuphorn, 2010), pointing movements on a touchscreen or to-
ward a pushbutton (Mirabella et al., 2006, 2011), single-joint
deflections of the elbow (McGarry and Franks, 1997; Kudo and
Ohtsuki, 1998), or some combination thereof (Brunamonti et al.,
2012). Distinct profiles of EMG activity are needed to control
distinct manual responses, reflecting differences in the specific
biomechanics and force requirements of the task. For someman-
ual responses, cancellation may entail the absence of departure
from a starting position, accomplished perhaps by withdraw-
ing or cancelling agonist muscle recruitment without requiring
antagonistmuscle recruitment; Scangos and Stuphorn (2010) did
not observe any antagonistmuscle recruitment in a task requiring
translation of a horizontal manipulandum. In our setup, antag-
onist muscle recruitment on proximal limbmuscles was detected
on 50% of successfully canceled trials even when the hand
stayed within a 1 cm radius window (Table 2).
Thus, successful cancellation in our task may or may not pro-
duce quantifiable changes in muscle recruitment. de Jong et al.
(1990) forwarded the notion of central or peripheral cancella-
tion, and our work and that of others (Burle et al., 2002; Servant
et al., 2015) extend this to a single-trial resolution. The presence
of trials where quantifiable changes in muscle recruitment were
absent does not detract from the value of such measures, when
available, in characterizing the stop process. Further, more ad-
vanced analytical methods may be able to extract peripheral sig-
natures of cancellation on an even higher proportion of canceled
trials, perhaps by assessing recruitment across multiple agonist
and antagonist muscles (Corneil et al., 2010) or within a higher-
dimensional space (Shenoy et al., 2013).
Using a trial-by-trial measure of movement cancellation to
study effects of trial history
Our results supported the hypothesis that the antagonist latency
is a manifestation of the stop process. We also found a relation-
ship between trial history and the recruitment timing of both
agonist (relative to target onset) and antagonist (relative to stop
signal onset)muscles. Thesemeasures trended in opposing direc-
tions after a stop trial, with antagonist latencies decreasing and
agonist latencies increasing across sequences with an intervening
stop trial. Such results are suggestive of proactive and opposing
adjustments that shift priority to expedite stop processes at the
expense of slowing go processes (Bissett and Logan, 2012a; Cor-
neil et al., 2013; Marcos et al., 2013). A novel finding of our study
is that the magnitude of such adjustment scales with the magni-
tude of the intervening error, with larger adjustments occurring
following larger errors. Thus, not only is the balance of stopping
Table 3. Mean antagonist latencies from canceled trials (in ms) for the selected and
unselected intramuscular recording, and the unselected surface recordinga
Subject
Selected
intramuscular
Unselected
intramuscular
Unselected
Surface
1 174 172 193
2 188 191 210
3 181 181 191
4 172 167 184
5 167 162 171
6 181 192 194
7 178 191 182
8 188 198 193
9 152 154 157
aAll recordings obtained from PEC.
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versus going affected by the presence of a stop trial, but adjust-
ments depend on the performance on that stop trial in a contin-
uous as opposed to binary fashion.
In contrast, both agonist and antagonist latencies decreased
across no-stop trial sequences, in contrast to that observed in the
oculomotor domain, where agonist latencies decreased while an-
tagonist latencies increased across a no-stop trial sequence (Cor-
neil et al., 2013). Our failure to replicate these previous results
may be because antagonist latencies on the neck were derived
from a small set of “head-only” errors when the headmoved even
though gaze remained stable (Goonetilleke et al., 2010, 2012).
Alternatively, the effects of trial history may be obscured by the
effect of movement amplitude on the n
 1 and n 1 stop trials
on the antagonist latency, or to the need to pool antagonist laten-
cies across PEC and DELT to obtain a sufficient number of stop–
no-stop–stop sequences, even though antagonist latencies were
13ms shorter on PEC.More precise analysis of how antagonist
latencies during manual responses change across a no-stop trial
sequence may require a unidirectional task to generate enough
such sequences with similar error amplitudes on the n 
 1 and
n 1 trials.
Challenges associated with assessing movement control
with EMG
Measuring antagonist latencies can advance the understanding of
movement inhibition, revealing, for example, evidence for pro-
active adjustments of inhibition based on trial history. Further,
providing a movement task is chosen that features prominent
antagonist muscle recruitment (in our case, occurring on75%
of all stop trials, or50%of canceled stop trials), accurate assess-
ments of inhibition via the antagonist latency can be obtained in
100 total trials, rather than the several hundreds or more re-
quired for accurate SSRT estimations (Band et al., 2003; Teichert
and Ferrera, 2015). Requiring fewer trials may help assessment of
clinical or pediatric populations not amenable to performing a
large number of trials. Study of such populations is also potenti-
ated by our findings that antagonist recruitment can be recorded
via surface EMG.
Assessing inhibition via EMG measurements does present
challenges. Single-trial EMGmeasures are noisy, requiring com-
plex algorithms to detect burst onset or offset and separate signal
from noise. The limb is also a complex and asymmetric motor
plant, requiring informed choices of agonist and antagonistmus-
cles. In our study, PEC and DELT were not recruited symmetri-
cally as agonist-antagonist pairs, as was the case for bilaterally
recorded neck muscles (Goonetilleke et al., 2010); instead, PEC
servedmore of a primemover thanDELT, being recruited sooner
relative to target onset when serving as an agonist, and sooner
relative to stop signal onset when serving as an antagonist. The
magnitude and timing of control exerted through these muscles
are not identical, complicating analysis of trail history. Finally,
antagonist EMG signals associated with active braking may only
occur in conjunction with the motion of body parts endowed
with significant inertia, such as whole-arm reaching movements
or orienting head movements, and hence may be absent during
simpler joystick-, button-, or touchscreen-basedmovements. For
such movements, within-trial measures of cancellation may be
accessible via recordings of the withdrawal of agonist muscle
recruitment.
These challenges aside, the application of EMGwithin a coun-
termanding framework provides a rich dataset suited to trial-by-
trial examination that can advance the neurophysiological and
theoretical understanding of movement inhibition. We note as
well that our use of EMGwithin the countermanding framework
parallels the rise of using EMG recordings, down to the level of
single trials, to advance the understanding of how the brain ar-
rives at decisions (Burle et al., 2002; Servant et al., 2015; Jana et al.,
2017).
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